Clinical Trial VICCPHI1342


A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects with Advanced Solid Tumors

Principal Investigator(s)

Emily Chan


  • Protocol No. VICCPHI1342
  • Open Date: 02/11/2014
  • Staging: Phase I
  • Age Group: Adults
  • Scope: National
  • Objective: - Evaluate the safety and tolerability of AMG 337. - Characterize the PK of AMG 337 when administered orally as once daily (QD) and twice daily (BID) doses. - Determine the maximum tolerated dose (MTD) of AMG 337 based on the QD dose escalation cohort, if possible.
  • Disease Sites: Phase I
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: AMG 337
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01253707
  • Secondary Protocol No: 20101132



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.